Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis.

Published in:

Oncologist, 2019, v. 24, n. 7, p. 955, doi. 10.1634/theoncologist.2018-0538

By:

• Bair, Steven M.;
• Strelec, Lauren E.;
• Feldman, Tatyana A.;
• Ahmed, Gulrayz;
• Armand, Philippe;
• Shah, Nirav N.;
• Singavi, Arun N.;
• Reddy, Nishitha;
• Khan, Nadia;
• Andreadis, Charalambos;
• Vu, Khoan;
• Huntington, Scott F.;
• Giri, Smith;
• Ujjani, Chaitra;
• Howlett, Christina;
• Faheem, Malik;
• Youngman, Matthew R.;
• Nasta, Sunita D.;
• Landsburg, Daniel J.;
• Schuster, Stephen J.

Publication type:

Article